Variations of prothrombin time and international normalized ratio in patients treated with warfarin

Thrombosis Research

Volumn 107, Issue 5, 2002, Pages 277-280

  Ho, Chao Hung ^a,b   Lin, Ming Wei ^a   You, Jie Yu ^a   Chen, Chih Cheng ^a   Yu, Tarng Jenn ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Anticoagulant therapy; Different time periods; International normalized ratio; Prothrombin time

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ALCOHOLIC BEVERAGE; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPOTHESIS; INTERNATIONAL STANDARD UNIT; KIDNEY FUNCTION; LIVER FUNCTION; MEASUREMENT; MONITOR; PRIORITY JOURNAL; PROTHROMBIN TIME; SCREENING TEST; STANDARD; THROMBOCYTE COUNT; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MONITORING; FEMALE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; STATISTICAL ANALYSIS; TAIWAN; TIME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CIRCADIAN RHYTHM; DATA INTERPRETATION, STATISTICAL; DRUG MONITORING; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN TIME; TAIWAN; TIME FACTORS; WARFARIN;

EID: 0036761812     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00339-0     Document Type: Article

References (12)

1. Hillman R.S., Ault K.A. Thrombotic disorders. Hillman R.S., Ault K.A. Hematology in Clinical Practice. 1995;498-525 McGraw-Hill, New York.
2. Serlin M.J., Breckenridge A.M. Drug interactions with warfarin. Drugs. 25:1983;610-620.
3. Bleske B.E., Welage L.S., Warren E.W., Brown M.B., Shea M.J. Variations in prothrombin time and international normalized ratio over 24 hours in warfarin-treated patients. Pharmacotherapy. 15:1995;709-712.
4. van den Besselaar A.M.H.P. Oral anticoagulant therapy. Bloom A.L., Forbes C.D., Thomas D.P., Tuddenham E.G.D. Haemostasis and Thrombosis. 3rd ed. 1994;1439-1457 Churchill Livingstone, Tokyo.
5. Soulban G., Labrecque G. Temporal variation in the effects of warfarin on the vitamin K cycle. Chronobiol. Int. 7:1990;403-411.
6. Soulban G., Labrecque G. Biological rhythms of blood coagulation and of the effect of warfarin in rats. Annu. Rev. Chronopharmacol. 5:1988;465-468.
7. Chan C.W., Hoaglund F.T. Pulmonary thromboembolism and venous thrombosis in Chinese. Clin. Orthop. 150:1980;253-260.
8. Cheng K.K., Lai S.T., Yu T.J., Duo S.M. Postoperative deep vein thrombosis in the Taiwanese Chinese population. Am. J. Surg. 153:1987;302-305.
9. Ho C.H. Prevalence of activated protein C resistance in the Chinese population. Thromb. Res. 88:1997;409-412.
10. Ho C.H., Chau W.K., Hsu H.C., Gau J.P., Chih C.M. Prevalence of factor V Leiden in the Chinese population. Chin. Med. J. (Taipei). 62:1999;875-878.
11. Ho C.H. Prevalence of prothrombin 20210 A allele and methylenetetrahydrofolate reductase C677T genetic mutations in the Chinese population. Ann. Hematol. 79:2000;239-242.
12. Woo K.S., Tse L.K.K., Tse C.Y., Metreweli C., Vallance-Owen J. The prevalence and pattern of pulmonary thromboembolism in the Chinese in Hong Kong. Int. J. Cardiol. 20:1988;373-380.